A searchable index of real negative results, null findings, and replication failures from the published literature — so you can learn what didn't work before repeating it.
WASTE indexes published research — it does not host or republish full papers. Each entry is a metadata record (title, authors, DOI) compiled from open scholarly databases, with the abstract shown in full only where the paper is openly licensed (e.g. Creative Commons); otherwise a short excerpt is shown for reference under fair use. WASTE classifies each work by failure type; classifications are automated and approximate.
21253 results · page 186 of 709
Koch MW, Sage K, Kaur S et al. · 2021 · Neurology
Objective To assess whether treatment with the generic drug domperidone can reduce the progression of disability in secondary progressive multiple sclerosis (SPMS), we conducted a phase 2 futility trial following the Simon 2-stage design.…
Wilky BA, Julian KA, Maleddu A et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose Doxorubicin is standard chemotherapy for metastatic soft tissue sarcomas (STS) but also enhances innate/adaptive immune responses by inducing immunogenic cell death. Most STS are immune "cold" tumors that do not respond to immune…
Xu J, Keenan TE, Overmoyer B et al. · 2021 · Preprint
Abstract Purpose: We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations.…
Xu J, Keenan TE, Overmoyer B et al. · 2021 · Breast cancer research and treatment
Purpose We evaluated the efficacy and safety of poly-(adenosine diphosphate-ribose) polymerase (PARP) 1 and 2 inhibitor veliparib and temozolomide in metastatic breast cancer patients with and without germline BRCA1/2 mutations. Methods In…
Comi G, Dadon Y, Sasson N et al. · 2022 · Multiple sclerosis (Houndmills, Basingstoke, England)
Background Interventions targeting the adaptive immune response are needed in multiple sclerosis (MS). Objective Evaluate laquinimod's efficacy, safety, and tolerability in patients with relapsing-remitting multiple sclerosis (RRMS).…
Manzo A, Sforza V, Carillio G et al. · 2022 · Frontiers in oncology
Few treatment options are available for patients with small cell lung cancer (SCLC) in progression after a first-line therapy. A novel therapeutic approach is represented by lurbinectedin, a synthetic derivative of trabectedin that works…
Schiphorst AT, Arquizan C, Turc G et al. · 2026 · Journal of stroke
Background and purpose Whether perfusion-diffusion mismatch modifies treatment effect of mechanical thrombectomy (MT) for large strokes is poorly known. To address this question, we conducted a post hoc secondary analysis of the Large…
Marder G, Quach T, Chadha P et al. · 2024 · Rheumatology (Oxford, England)
Objective To evaluate belimumab addition to the standard of care in patents with refractory idiopathic inflammatory myopathy (IIM). Methods We conducted a 40-week multicentre, randomized, double-blind, placebo-controlled trial with 1:1 IV…
White RA, Mezzano-Robinson V, Shi Q et al. · 2025 · The oncologist
Background The parasympathetic branch of the autonomic nervous system has shown tumor-suppressive effects in preclinical models of pancreatic adenocarcinoma (PDAC) by inhibiting cancer stem cells and suppressing inflammatory cytokine…
Zhang CD, Zhou JS, He LY et al. · 2025 · Frontiers in cardiovascular medicine
Objective The aim of this study was to investigate the quantitative flow ratio (QFR) outcomes in the left circumflex artery (LCX) following the placement of a crossover stent from the left main coronary artery (LM) to the left anterior…
Raychaudhuri R, Cheng HH, Gulati R et al. · 2026 · European urology oncology
Background and objective Our aim was to determine whether induction chemotherapy followed by PARP inhibitor (PARPi) maintenance improves outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC) harboring…
Choi SW, Jung HA, Cho HJ et al. · 2023 · Cancer medicine
Background We evaluated the therapeutic efficacy of GC1118, a novel anti-epidermal growth factor receptor (EGFR) monoclonal antibody, in recurrent glioblastoma (GBM) patients with EGFR amplification. Methods This study was a multicenter,…
Voglová B, Hladíková Z, Nemétová L et al. · 2020 · American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Early worsening of diabetic retinopathy due to sudden glucose normalization is a feared complication of pancreas transplantation; however, its rate or severity has not been studied prospectively. We followed up 43 pancreas and kidney…
Breen WG, Dixon JG, Anderson SK et al. · 2025 · Neuro-oncology
Background Dasatinib is an oral inhibitor of the Src kinase family, with preclinical data indicating impact on gliomagenesis, tumor invasion, and radiosensitivity. Methods North Central Cancer Treatment Group N0877 is a phase 1 dose…
Jacobsen LM, Schatz D · 2025 · Hormone research in paediatrics
Background Type 1 diabetes (T1D) is more than an insulin-deficiency disease - it is an autoimmune disease, and the field is moving toward adopting disease-modifying immunotherapy as part of clinical care during T1D development. Summary…
Çalışkan B · 2025 · International ophthalmology
Purpose To evaluate serum lipid profiles with triglyceride-Glucose (TyG) and TG/HDL-c indices in patients with exudative type age-related macular degeneration. Methods A total of 71 participants were included in the study: 35 with…
Davidson TM, Lebreton CL, Hendricksen AEW et al. · 2023 · Gynecologic oncology
Background IGF signaling has been implicated in the pathogenesis and progression of ovarian carcinoma (OC). Single agent activity and safety of ganitumab (AMG 479), a fully human monoclonal antibody against IGF1R that blocks binding of…
O'Hara MH, Jegede O, Dickson MA et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose Amplification of cyclin-dependent kinase 4 (CDK4) and CDK6 is a feature of a variety of malignancies, and preclinical evidence suggests that inhibition of CDK4/6 is a plausible treatment strategy in these tumors. Subprotocol Z1C of…
Taccetti G, Terlizzi V, Campana S et al. · 2024 · European journal of pediatrics
Bacterial infections of the lower airways are the main cause of mortality and morbidity in cystic fibrosis. The most frequently isolated pathogens are S. aureus and P. aeruginosa; bacterial co-infections are frequently observed. The aim of…
Schott CA, Mohning MP, Cooley JC · 2025 · Seminars in respiratory and critical care medicine
Idiopathic pulmonary fibrosis (IPF) is a rare but devastating diagnosis for patients with only two approved drug therapies. Extensive preclinical studies have identified and characterized novel pathways driving IPF pathogenesis, and…
Mosca M, Arnaud L, Askanase A et al. · 2025 · Lupus science & medicine
Objective In PAISLEY, a 48-week, phase II, randomised controlled trial that assessed deucravacitinib in patients with active SLE, all primary and secondary endpoints were met with the deucravacitinib 3 mg two times per day dose. Changes in…
Bateman RJ, Li Y, McDade EM et al. · 2025 · The Lancet. Neurology
Background Amyloid plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The…
Hamamoto H, Suzuki Y, Takano Y et al. · 2022 · BMC surgery
Background This retrospective study aimed to compare long-term oncological outcomes between laparoscopic-assisted colectomy (LAC) with extracorporeal anastomosis (EA) and totally laparoscopic colectomy (TLC) with intracorporeal anastomosis…
Borghaei H, O'Byrne KJ, Paz-Ares L et al. · 2023 · ESMO open
Background In CheckMate 227 Part 1, first-line nivolumab plus ipilimumab prolonged overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) and tumor programmed death-ligand 1 (PD-L1) expression ≥1% versus…
Cacko A, Kozyra-Pydyś E, Gawałko M et al. · 2021 · Cardiology journal
Background Among patients with an implanted cardiac implantable electronic device (CIED), ipsilateral upper extremity vein stenosis or occlusion (VSO) is observed more frequently than in the general population. However, there are no data…
Choueiri TK, Albiges L, Barthélémy P et al. · 2024 · Lancet (London, England)
Background Immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor tyrosine kinase inhibitors are cornerstones of first-line treatment for advanced renal cell carcinoma; however, optimal treatment sequencing…
Konno Y, Mayama M, Takehara K et al. · 2025 · Journal of gynecologic oncology
Objective This study aimed to assess the prognostic significance of para-aortic lymphadenectomy (PALX) and para-aortic lymph node metastasis in endometrial cancer (EC) patients at risk of post-operative recurrence. Methods Japanese…
Pettengell R, Długosz-Danecka M, Andorsky D et al. · 2020 · British journal of haematology
PIX306 was a phase 3, randomised, single-blind, multicentre trial conducted in adult patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) grade 3 who relapsed after ≥1 rituximab-containing regimen and were not…
Tolaney SM, Sahebjam S, Le Rhun E et al. · 2020 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose The primary objective was to evaluate intracranial objective response rate (iORR) in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary to hormone receptor-positive (HR + ) metastatic breast…
Rascol O, Tönges L, deVries T et al. · 2022 · Parkinsonism & related disorders
Background Immediate-release (IR) amantadine has been used for treatment of levodopa induced dyskinesia (LID). The immediate-release/extended-release (IR/ER) amantadine formulation OS320 (OSMOLEX ER®) contains an IR outer layer and ER core…